Latest

Learn how antibiotic-resistant UTI testing identifies ESBL, CRE, resistance genes, and antibiotic susceptibility, and how culture results guide treatment and follow-up.

Antibiotic-Resistant UTI Test: ESBL, CRE, Resistance Markers, and Culture Meaning

Learn what asymptomatic bacteriuria means, how a positive urine culture without UTI symptoms is interpreted, and when screening, treatment, or follow-up matters.

Asymptomatic Bacteriuria Test: Positive Culture Without Symptoms and When It Matters

Learn how bacteria in urine are interpreted using urinalysis, culture, colony count, symptoms, and sample quality, including when contamination or follow-up testing matters.

Bacteria in Urine Test: UTI, Contamination, Colony Count, and Culture Follow-Up

Learn how a catheter urine culture helps diagnose catheter-associated UTI, how samples are collected, and what colony counts, pyuria, resistance, and positive results mean.

Catheter Urine Culture Test: Catheter-Associated UTI and Culture Meaning

Learn how a chlamydia and gonorrhea urine NAAT works, how to collect first-catch urine, what positive or negative results mean, and when follow-up testing is needed.

Chlamydia and Gonorrhea Urine NAAT Test: STI Screening, Positive Result, and Meaning

Learn how to collect a clean-catch urine culture, reduce contamination, handle the sample correctly, and understand mixed flora, colony counts, repeat testing, and accurate results.

Clean-Catch Urine Culture Test: Sample Collection, Contamination, and Accurate Results

Diagnostics

Home Diagnostics Page 30

Understand IDH1 and IDH2 Test for Cholangiocarcinoma Mutation Status and Molecular Meaning: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

IDH1 and IDH2 Test for Cholangiocarcinoma: Mutation Status and Molecular Meaning

Understand KRAS Test for Colon Cancer Mutation Status, Anti-EGFR Resistance Marker, and Meaning: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

KRAS Test for Colon Cancer: Mutation Status, Anti-EGFR Resistance Marker, and...

Understand KRAS Test for Pancreatic Cancer Tumor Mutation, Mutation Status, and Diagnostic Context: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

KRAS Test for Pancreatic Cancer: Tumor Mutation, Mutation Status, and Diagnostic...

Understand Liver Cancer Biomarker Panel AFP, DCP, PIVKA-II, AFP-L3, and HCC Risk: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

Liver Cancer Biomarker Panel: AFP, DCP, PIVKA-II, AFP-L3, and HCC Risk

Understand MLH1 Promoter Methylation Test Colon Cancer, Lynch Syndrome Workup, and Sporadic MSI: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

MLH1 Promoter Methylation Test: Colon Cancer, Lynch Syndrome Workup, and Sporadic...

Understand MMR IHC Test for Colon Cancer MLH1, MSH2, MSH6, PMS2, and Lynch Screening: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

MMR IHC Test for Colon Cancer: MLH1, MSH2, MSH6, PMS2, and...

Learn what MSI-H, dMMR, MSS, and pMMR mean in colon cancer, how MSI testing guides immunotherapy, and when an abnormal result can lead to Lynch syndrome testing.

MSI Test for Colon Cancer: Microsatellite Instability, Lynch Syndrome, and Mismatch...

Understand MSI testing in gastric cancer, including MSI-H, dMMR, MSS, molecular subtype, immunotherapy relevance, and when a result may prompt Lynch syndrome evaluation.

MSI Test for Gastric Cancer: Microsatellite Instability, Mismatch Repair, and Molecular...

Learn what an NRAS mutation means in colon cancer, why NRAS predicts resistance to cetuximab and panitumumab, and how wild-type results fit into extended RAS testing.

NRAS Test for Colon Cancer: Mutation Status, Anti-EGFR Resistance Marker, and...

Learn how NTRK fusion testing works in colon cancer, what a positive fusion means, why NTRK is a tumor-agnostic marker, and how TRK inhibitors may be used in advanced disease.

NTRK Fusion Test for Colon Cancer: Gene Fusion, Tumor-Agnostic Marker, and...

Learn how the Oncotype DX Colon Recurrence Score works, what a 0–100 genomic score means, and how it can refine recurrence-risk discussions after colon cancer surgery.

Oncotype DX Colon Recurrence Score Test: Colon Cancer Recurrence Risk and...

Learn what a PALB2 result means in pancreatic cancer, how germline and tumor variants differ, why platinum sensitivity matters, and when hereditary family testing is needed.

PALB2 Test for Pancreatic Cancer: DNA Repair Marker, Hereditary Risk, and...

Understand pancreatic cancer biomarkers including CA 19-9, CEA, KRAS, BRCA, PALB2, MSI, and gene fusions, with practical guidance on monitoring, hereditary risk, and targeted therapy.

Pancreatic Cancer Biomarker Panel: CA 19-9, CEA, KRAS, BRCA, PALB2, and...

Learn how PD-L1 CPS is calculated in gastric cancer, what CPS ≥1 and CPS ≥5 mean, and how expression level guides immunotherapy alongside HER2 and MSI testing.

PD-L1 Test for Gastric Cancer: CPS Score, Expression Level, and Immunotherapy...

Learn what a high PIVKA-II or DCP result means, which noncancer conditions can raise it, and how the marker is used with AFP and imaging for HCC risk and monitoring.

PIVKA-II Test for Liver Cancer: High Levels, HCC Risk, and Monitoring

Learn how Signatera uses tumor-informed ctDNA to detect molecular residual disease after colon cancer treatment, what positive and negative results mean, and how MRD monitoring may guide care.

Signatera Test for Colon Cancer: ctDNA Recurrence Monitoring and MRD Detection

1...293031...137 Page 30 of 137